Stockholm3 in a Multiethnic Cohort: Optimizing Prostate Cancer Screening to Reduce Harm and Improve Equity Historically, the sharing of CSRs and IPD by trial sponsors, both in academia and industry, ...
GenAI-powered solution delivers clinical study reports in minutes with 30%–50% faster turnarounds, 90% ICH-E3-aligned accuracy, and substantial cost savings. BERKELEY HEIGHTS, N.J., Feb. 4, 2025 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results